Drug Profile
Fluticasone propionate inhalation - Teva Pharmaceutical Industries
Alternative Names: Aermony RespiClick; ArmonAir Digihaler; ArmonAir RespiClick; Fluticasone propionate MDPI; Fluticasone propionate MDPI - Teva Pharmaceutical Industries; Fluticasone propionate RespiClickLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 05 Oct 2020 Launched for Asthma (In adolescents, In adults) in Canada (Inhalation)
- 22 Sep 2020 Teva Pharmaceutical launches (ArmonAir® Digihaler™) fluticasone propionate for Asthma (In adults, In adolescents) in USA (Inhalation)
- 24 Feb 2020 The US FDA approves (ArmonAir® Digihaler™) fluticasone propionate for Asthma (In adults, In adolescents) in USA (Inhalation)